In October 2024, Lutris successfully completed enrollment in the international phase 2 trial of LUT014 in patients with metastatic colorectal cancer (mCRC) treated with EGFRi therapy who develop ...

Basically, ERAS targets RAS/MAPK pathways, which helps prevent cancerous ... The first one is for KRAS-mutated solid tumors, and the latter is for EGFR and RAS/MAPK solid tumors.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Phosphoproteomic arrays and specific inhibitors revealed that CSC-mediated E6/E7 overexpression is at least in part reliant on EGFR phosphorylation. In addition, we showed that the PI3K/Akt pathway is ...

EGFR, PPP3CB, and MYO5A expression was significantly associated ... endocrine and other factor-regulated calcium reabsorption, and MAPK signaling pathway. The enriched pathways for candidate target ...

Yeah, so the EGFR mutation lung cancer field has really expanded. We usually think about EGFR as the classical mutation, deletion 19 and 858R mutation. But in the last, I will say, five to 10 ...

When I encounter a newly diagnosed EGFR mutation lung cancer, especially a metastatic stage patient, usually tell them that the patient will sequentially receive different type of treatment.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Here, we report that endosomal-localized EGFR/Ezrin complex interacts with and triggers the inhibition of the Tuberous Sclerosis Complex (TSC complex) in response to EGF stimuli. This is regulated ...

1Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China. 2Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Benxi, China. Search for other works ...